Cancers,
Год журнала:
2024,
Номер
16(24), С. 4164 - 4164
Опубликована: Дек. 13, 2024
Breast
cancer
is
the
most
frequently
diagnosed
neoplasm
all
over
world
and
second
leading
cause
of
death
in
women.
prognosis
has
significantly
improved
last
years
due
to
advent
novel
therapeutic
options,
both
early
advanced
stages.
However,
spread
disease
brain,
accounting
for
15–30%
metastatic
diagnoses,
challenging,
its
poor
represents
an
unmet
medical
need,
deterioration
quality
life
causing
morbidity
mortality.
Generally,
triple-negative
HER2-positive
breast
subtypes
more
brain
or
leptomeningeal
space.
Consequently,
according
international
guidelines,
several
systemic
treatments
can
be
offered
as
a
first
option
some
subsets
patients.
multidisciplinary
approach
recommended
offer
appropriate
strategy
Antibody–drug
conjugates
such
trastuzumab
deruxtecan
sacituzumab
govitecan
along
with
small
molecules
have
led
important
achievements
treatment
metastases
from
cancer.
In
this
narrative
review,
we
will
focus
on
molecular
features
development
explore
risk
prognostic
factors
involved
metastases.
Finally,
review
major
landscape
approaches.
